OpenEvidence Partners with Society of Surgical Oncology to Expand Cancer Care Knowledge Platform
Event summary
- OpenEvidence and the Society of Surgical Oncology (SSO) have formed a strategic partnership to integrate SSO's clinical content and educational resources into OpenEvidence's platform.
- The collaboration aims to enhance access to surgical oncology evidence at the point of care, supporting surgeons and other physicians in cancer treatment.
- A cornerstone of the partnership is the SSO Innovator Grant, a 24-month research award launching in Summer 2026 to support surgeon-led innovation in AI-enabled medical knowledge and clinical decision support tools.
- Ken Tanabe, MD, President of SSO, and Travis Zack, MD, PhD, Chief Medical Officer at OpenEvidence, highlighted the partnership's potential to improve cancer care outcomes.
The big picture
This partnership aligns with the broader trend of leveraging AI and digital platforms to enhance medical knowledge dissemination and clinical decision-making. By combining SSO's expertise in surgical oncology with OpenEvidence's widely used medical AI platform, the collaboration aims to address the growing complexity and volume of medical evidence, particularly in cancer care. The introduction of the SSO Innovator Grant underscores a strategic focus on fostering innovation in AI-enabled clinical tools, potentially setting a new standard for medical knowledge platforms.
What we're watching
- Integration Impact
- How the integration of SSO's content into OpenEvidence's platform will affect the adoption and utilization of surgical oncology evidence among physicians.
- Innovation Acceleration
- Whether the SSO Innovator Grant will successfully drive surgeon-led innovation in AI-enabled medical knowledge and clinical decision support tools.
- Market Expansion
- The pace at which this partnership will expand OpenEvidence's reach beyond surgical oncologists to other physicians involved in cancer care.
Related topics